Clinical Trial Update: Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial updating the combination of gemcitabine with or without erlotinib in unresectable locally advanced or metastatic pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: NCIC Clinical Trials Group | Conditions: Pancreatic Cancer | Phase 3 | Status: COMPLETED